Ildong Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-03-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ildong.com
Clinical Trials
50
Active:0
Completed:24
Trial Phases
5 Phases
Phase 1:24
Phase 2:1
Phase 3:13
+2 more phases
Drug Approvals
2
PHILIPPINES:2
Clinical Trials
Distribution across different clinical trial phases (43 trials with phase data)• Click on a phase to view related trials
Phase 1
24 (55.8%)Phase 3
13 (30.2%)Phase 4
3 (7.0%)Not Applicable
2 (4.7%)Phase 2
1 (2.3%)Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects
Phase 1
Recruiting
- Conditions
- Healthy Adult Subjects
- Interventions
- Drug: Placebo of 110521156
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT06635226
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Adult Subjects
- Interventions
- Drug: Placebo of ID110521156
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT06063291
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 86
- Registration Number
- NCT05663879
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 67
- Registration Number
- NCT05604287
- Locations
- 🇺🇸
California Clinical trials medical group/PAREXEL, Glendale, California, United States
To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers
Phase 1
- Conditions
- DyslipidemiasHypertension
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT05259020
- Locations
- 🇰🇷
H plus yangji hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
No news found